Robert C. Thompson spends much of his time researching Molecular biology, Genome-wide association study, Schizophrenia, Major depressive disorder and Receptor. His Molecular biology study incorporates themes from Amino acid, Biochemistry, Binding site, Complementary DNA and Peptide sequence. His work in Genome-wide association study covers topics such as Genetic association which are related to areas like Comorbidity, Risk factor, Heritability and Clinical psychology.
His Major depressive disorder research incorporates Genetic heterogeneity and Growth factor receptor. His work on Receptor antagonist and Interleukin 1 receptor antagonist as part of general Receptor study is frequently connected to Biological activity and TNF inhibitor, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Gene expression research integrates issues from Internal medicine and Endocrinology.
Robert C. Thompson mostly deals with Molecular biology, Internal medicine, Endocrinology, Biochemistry and Gene. Robert C. Thompson has researched Molecular biology in several fields, including Cellular differentiation, RNA, Complementary DNA, Receptor and Messenger RNA. Robert C. Thompson combines subjects such as Regulation of gene expression and ASCL1, Transcription factor with his study of Cellular differentiation.
Robert C. Thompson performs integrative study on Endocrinology and Major depressive disorder. He integrates Major depressive disorder and Genetic heterogeneity in his studies. His research links Schizophrenia with Genome-wide association study.
Robert C. Thompson focuses on Gene, Genetics, Gene expression, Major depressive disorder and Genome-wide association study. His work in Gene addresses issues such as Cell biology, which are connected to fields such as Single-cell analysis, Cell, Regulation of gene expression, Distribution and Cloning. Robert C. Thompson has included themes like Hippocampal formation and Cell type in his Gene expression study.
Major depressive disorder is integrated with Fibroblast growth factor, Growth factor, Endocrinology and Internal medicine in his research. His biological study spans a wide range of topics, including Genetic heterogeneity, Genetic association and Schizophrenia. His research in Genetic heterogeneity intersects with topics in Heritability, Risk factor, Clinical psychology and Comorbidity.
The scientist’s investigation covers issues in Genome-wide association study, Major depressive disorder, Schizophrenia, Neuroscience and Genetics. His Genome-wide association study study frequently draws connections between adjacent fields such as Genetic association. His Genetic association study combines topics from a wide range of disciplines, such as Biological pathway, Psychiatry, Genomics, Histone methylation and Psychiatric genetics.
His Neuroscience study integrates concerns from other disciplines, such as Basal and Gene expression. Robert C. Thompson usually deals with Genetics and limits it to topics linked to Psychosis and Copy-number variation, Multifactorial Inheritance, Disease and Age of onset. The various areas that he examines in his Genetic heterogeneity study include Heritability, Risk factor, Clinical psychology and Comorbidity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs
S. Hong Lee;Stephan Ripke;Stephan Ripke;Benjamin M. Neale;Benjamin M. Neale;Stephen V. Faraone.
Nature Genetics (2013)
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Charles H. Hannum;Carol J. Wilcox;William P. Arend;Fenneke G. Joslin.
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Simon I Hay;Amanuel Alemu Abajobir;Kalkidan Hassen Abate;Cristiana Abbafati.
The Lancet (2017)
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist
Stephen P. Eisenberg;Ron J. Evans;William P. Arend;Evie Verderber.
Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.
Kjell Ohlsson;Peter Björk;Magnus Bergenfeldt;Robert Hageman.
Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4
Pamela Sklar;Pamela Sklar;Stephan Ripke;Stephan Ripke;Laura J. Scott;Ole A. Andreassen.
Nature Genetics (2011)
Mu, Delta, and Kappa Opioid Receptor mRNA Expression in the Rat CNS: An In Situ Hybridization Study
Alfred Mansour;Charles A. Fox;Sharon Burke;Fan Meng.
The Journal of Comparative Neurology (1994)
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
William P. Arend;Howard G. Welgus;Robert C. Thompson;Stephen P. Eisenberg.
Journal of Clinical Investigation (1990)
Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase
Robert C. Thompson;Kjell Ohlsson.
Proceedings of the National Academy of Sciences of the United States of America (1986)
Cloning and pharmacological characterization of a rat μ opioid receptor
Robert C. Thompson;Alfred Mansour;Huda Akil;Stanley J. Watson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: